Last reviewed · How we verify

NCT05392231: PS-GDM-2022

Assessment of Fetal Pancreatic Size and Maternal Serum Biomarkers in GDM

Completed Last updated 1 June 2022
What this trial tests

trial in Gestational Diabetes in 109 participants. Completed in 10 May 2022.

Timeline
10 February 2022
Primary endpoint
30 April 2022
10 May 2022

Quick facts

Lead sponsorHaseki Training and Research Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment109
Start date10 February 2022
Primary completion30 April 2022
Estimated completion10 May 2022
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Haseki Training and Research Hospital

Who can join

Adults 18 to 42, female only, with Gestational Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabetes mellitus (GDM).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Fetal pancreas size and maternal serum biomarkers glycated albumin and insulin-regulated aminopeptidase provide no potential for early prediction of gestational diabetes mellitus.
    Guleroglu FY, Ozmen AB, Bakirci IT, Dogu SY, et al · · 2023 · cited 7× · PMID 36436013 · DOI 10.1007/s00404-022-06860-2

Verify or expand the search:

Other recruiting trials for Gestational Diabetes

Currently open trials in the same condition.

Other Haseki Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05392231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing